vs
Side-by-side financial comparison of Viridian Therapeutics, Inc.\DE (VRDN) and WIDEPOINT CORP (WYY). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $42.3M, roughly 1.7× WIDEPOINT CORP). WIDEPOINT CORP runs the higher net margin — -2.0% vs -49.0%, a 47.0% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 12.3%). WIDEPOINT CORP produced more free cash flow last quarter ($-270.0K vs $-84.7M).
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
WidePoint Corporation is an American company based in Fairfax, Virginia that provides technology-based products and services to the government sector and commercial markets in the United States. The company holds a patent for a digital parsing tool that allows users to access accounts through a secure repository gateway, established using asymmetric authentication employed as public key infrastructure (PKI). WidePoint provides smart card identity verification, wireless expense management, pen...
VRDN vs WYY — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $70.6M | $42.3M |
| Net Profit | $-34.6M | $-849.4K |
| Gross Margin | — | 13.8% |
| Operating Margin | -56.7% | -1.9% |
| Net Margin | -49.0% | -2.0% |
| Revenue YoY | 81958.1% | 12.3% |
| Net Profit YoY | 54.9% | -138.3% |
| EPS (diluted) | — | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $42.3M | ||
| Q3 25 | $70.6M | $36.1M | ||
| Q2 25 | — | $37.9M | ||
| Q1 25 | — | $34.2M | ||
| Q4 24 | — | $37.7M | ||
| Q3 24 | — | $34.6M | ||
| Q2 24 | — | $36.0M | ||
| Q1 24 | — | $34.2M |
| Q4 25 | — | $-849.4K | ||
| Q3 25 | $-34.6M | $-559.2K | ||
| Q2 25 | — | $-618.5K | ||
| Q1 25 | — | $-724.1K | ||
| Q4 24 | — | $-356.4K | ||
| Q3 24 | — | $-425.2K | ||
| Q2 24 | — | $-499.6K | ||
| Q1 24 | — | $-653.1K |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 14.6% | ||
| Q2 25 | — | 13.5% | ||
| Q1 25 | — | 14.0% | ||
| Q4 24 | — | 12.6% | ||
| Q3 24 | — | 13.6% | ||
| Q2 24 | — | 13.6% | ||
| Q1 24 | — | 13.6% |
| Q4 25 | — | -1.9% | ||
| Q3 25 | -56.7% | -1.3% | ||
| Q2 25 | — | -1.9% | ||
| Q1 25 | — | -2.4% | ||
| Q4 24 | — | -0.8% | ||
| Q3 24 | — | -1.3% | ||
| Q2 24 | — | -1.3% | ||
| Q1 24 | — | -1.9% |
| Q4 25 | — | -2.0% | ||
| Q3 25 | -49.0% | -1.5% | ||
| Q2 25 | — | -1.6% | ||
| Q1 25 | — | -2.1% | ||
| Q4 24 | — | -0.9% | ||
| Q3 24 | — | -1.2% | ||
| Q2 24 | — | -1.4% | ||
| Q1 24 | — | -1.9% |
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | $-0.05 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.05 | ||
| Q1 24 | — | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $490.9M | $9.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $503.0M | $11.5M |
| Total Assets | $577.1M | $79.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $9.8M | ||
| Q3 25 | $490.9M | $12.1M | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | — | $3.7M | ||
| Q4 24 | — | $6.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $11.5M | ||
| Q3 25 | $503.0M | $12.2M | ||
| Q2 25 | — | $12.6M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $13.6M | ||
| Q3 24 | — | $13.8M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $14.2M |
| Q4 25 | — | $79.8M | ||
| Q3 25 | $577.1M | $70.6M | ||
| Q2 25 | — | $76.6M | ||
| Q1 25 | — | $71.4M | ||
| Q4 24 | — | $71.6M | ||
| Q3 24 | — | $56.9M | ||
| Q2 24 | — | $58.6M | ||
| Q1 24 | — | $54.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-84.6M | $-173.5K |
| Free Cash FlowOCF − Capex | $-84.7M | $-270.0K |
| FCF MarginFCF / Revenue | -120.1% | -0.6% |
| Capex IntensityCapex / Revenue | 0.2% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-173.5K | ||
| Q3 25 | $-84.6M | $5.9M | ||
| Q2 25 | — | $3.2M | ||
| Q1 25 | — | $-3.2M | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | — | $-1.1M | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | $-270.0K | ||
| Q3 25 | $-84.7M | $5.9M | ||
| Q2 25 | — | $3.1M | ||
| Q1 25 | — | $-3.3M | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | — | $-1.1M | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | -0.6% | ||
| Q3 25 | -120.1% | 16.4% | ||
| Q2 25 | — | 8.1% | ||
| Q1 25 | — | -9.5% | ||
| Q4 24 | — | 6.4% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | -3.0% | ||
| Q1 24 | — | -4.6% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | 0.2% | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VRDN
Segment breakdown not available.
WYY
| Carrier Services | $26.8M | 63% |
| Managed Services | $15.5M | 37% |
